While loss-of-function (LOF) mutations in the epidermal barrier gene filaggrin (FLG) identified 16 years ago are still the strongest genetic risk factors for eczema, genome-wide approaches unraveled a number of involved pathways and contributed a plethora of candidate genes including some promising targets for therapeutic approaches. The gene discussed is FLG; the disease is Eczematoid dermatitis.